# Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer

> **NCT06291064** · PHASE2 · RECRUITING · sponsor: **University of Chicago** · enrollment: 85 (estimated)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Epirubicin
- **DRUG:** Docetaxel
- **DRUG:** Carboplatin
- **PROCEDURE:** Breast Surgery
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT06291064
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-18
- **Primary completion:** 2029-06
- **Final completion:** 2032-06
- **Target enrollment:** 85 (ESTIMATED)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06291064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06291064, "Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06291064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*